{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:41Z","timestamp":1792787861144,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Dubai","id":[{"id":"https:\/\/ror.org\/008qdx283","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04738-9","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:52:10Z","timestamp":1792669930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ethosome-based drug delivery system for precision targeting and tumour microenvironment reprogramming in non-invasive skin cancer therapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Madhavi","family":"Porwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik Belagodu","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javedh","family":"Shareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balamurugan","family":"Balusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phool","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"7","key":"4738_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamadermatol.2025.1276","volume":"161","author":"R Wang","year":"2025","unstructured":"Wang R, et al. Burden of skin cancer in older adults from 1990 to 2021 and modelled projection to 2050. JAMA Dermatol. 2025;161(7):715\u201322.","journal-title":"JAMA dermatology"},{"issue":"1","key":"4738_CR2","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1038\/s41598-025-90485-3","volume":"15","author":"L Zhou","year":"2025","unstructured":"Zhou L, et al. Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990\u20132021. Sci Rep. 2025;15(1):5996.","journal-title":"Sci Rep"},{"key":"4738_CR3","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules28155905","volume":"28","author":"M Adnan","year":"2023","unstructured":"Adnan M, et al. Exploring nanocarriers as treatment modalities for skin cancer. Molecules. 2023;28:5905.","journal-title":"Molecules"},{"key":"4738_CR4","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.62347\/JOUT3260","volume":"14","author":"M Xu","year":"2024","unstructured":"Xu M, Kong L, Jamil M. Advancements in skin cancer treatment: focus on photodynamic therapy: a review. Am J Cancer Res. 2024;14:5011.","journal-title":"Am J Cancer Res"},{"issue":"13","key":"4738_CR5","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.3390\/ijms25137056","volume":"25","author":"S Sol","year":"2024","unstructured":"Sol S, et al. Therapeutic approaches for non-melanoma skin cancer: standard of care and emerging modalities. Int J Mol Sci. 2024;25(13):7056.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4738_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/pharmaceutics17050583","volume":"17","author":"RM Almuqbil","year":"2025","unstructured":"Almuqbil RM, Bandar Aldhubiab. Ethosome-Based Transdermal Drug Delivery: Its Structural Components, Preparation Techniques, and Therapeutic Applications Across Metabolic, Chronic, and Oncological Conditions. Pharmaceutics. 2025;17(5):583.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4738_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.22270\/jddt.v9i3.2692","volume":"9","author":"V Pakhale Nilesh","year":"2019","unstructured":"Pakhale Nilesh V, Gondkar SB, Saudagar RB. Ethosomes: transdermal drug delivery system. J Drug Delivery Ther. 2019;9(3):729\u201333.","journal-title":"J Drug Delivery Ther"},{"issue":"6","key":"4738_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1039\/D2NA00530A","volume":"5","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Functional nano-systems for transdermal drug delivery and skin therapy. Nanoscale Adv. 2023;5(6):1527\u201358.","journal-title":"Nanoscale Adv"},{"issue":"2","key":"4738_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/08982104.2018.1517160","volume":"29","author":"N Nainwal","year":"2019","unstructured":"Nainwal N, et al. Transdermal applications of ethosomes: a detailed review. J Liposome Res. 2019;29(2):103\u201313.","journal-title":"J Liposome Res"},{"key":"4738_CR11","doi-asserted-by":"publisher","first-page":"1331355","DOI":"10.3389\/fonc.2024.1331355","volume":"14","author":"JA Bigos, Kamilla","year":"2024","unstructured":"Bigos, Kamilla JA, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front Oncol. 2024;14:1331355.","journal-title":"Front Oncol"},{"issue":"12","key":"4738_CR12","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cancers15123147","volume":"15","author":"N Kharouf","year":"2023","unstructured":"Kharouf N, et al. Tumor microenvironment as a therapeutic target in melanoma treatment. Cancers. 2023;15(12):3147.","journal-title":"Cancers"},{"issue":"1","key":"4738_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"V Petrova","year":"2018","unstructured":"Petrova V, et al. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10.","journal-title":"Oncogenesis"},{"key":"4738_CR14","doi-asserted-by":"publisher","first-page":"961637","DOI":"10.3389\/fonc.2022.961637","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, et al. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022;12:961637.","journal-title":"Front Oncol"},{"issue":"1","key":"4738_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Hu","year":"2025","unstructured":"Hu, Qin, et al. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol. 2025;18(1):65.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4738_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnol. 2024;22(1):737.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"4738_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res. 2024;12(1):96.","journal-title":"Biomark Res"},{"issue":"1","key":"4738_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Experimental Clin Cancer Res. 2021;40(1):24.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"2","key":"4738_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1021\/acs.molpharmaceut.3c00846","volume":"21","author":"N Zhang","year":"2024","unstructured":"Zhang N, et al. Advances in nanoplatforms for immunotherapy applications targeting the tumor microenvironment. Mol Pharm. 2024;21(2):410\u201326.","journal-title":"Mol Pharm"},{"issue":"1","key":"4738_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-021-01893-y","volume":"40","author":"H Li","year":"2021","unstructured":"Li H, et al. Underlying mechanisms and drug intervention strategies for the tumour microenvironment. J Experimental Clin Cancer Res. 2021;40(1):97.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"5","key":"4738_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"23","key":"4738_CR22","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1242\/jcs.116392","volume":"125","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(23):5591\u20136.","journal-title":"J Cell Sci"},{"issue":"3","key":"4738_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408.","journal-title":"Cell"},{"key":"4738_CR24","doi-asserted-by":"crossref","unstructured":"Vaupel P, Mayer A. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Oxygen Transp tissue XXXVI (2014): 19\u201324.","DOI":"10.1007\/978-1-4939-0620-8_3"},{"issue":"6","key":"4738_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Florian R, Greten KM. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399.","journal-title":"Cell"},{"issue":"4","key":"4738_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201102147","volume":"196","author":"P Lu","year":"2012","unstructured":"Lu P, Weaver VM, Zena Werb. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395\u2013406.","journal-title":"J Cell Biol"},{"issue":"12","key":"4738_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup MW, Janna K, Mouw, Valerie M. Weaver. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15(12):1243\u201353.","journal-title":"EMBO Rep"},{"issue":"4","key":"4738_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"4738_CR29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl j Med. 1971;285:1182\u20136.","journal-title":"N Engl j Med"},{"issue":"5","key":"4738_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605\u201322.","journal-title":"Cancer Cell"},{"issue":"45","key":"4738_CR31","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"LT Whiteside","year":"2008","unstructured":"Whiteside L T. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904\u201312.","journal-title":"Oncogene"},{"issue":"4","key":"4738_CR32","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/ijms20040840","volume":"20","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.","journal-title":"Int J Mol Sci"},{"key":"4738_CR33","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S0169-409X(02)00113-8","volume":"54","author":"BW Barry","year":"2002","unstructured":"Barry BW. Drug delivery routes in skin: a novel approach. Adv Drug Deliv Rev. 2002;54:S31\u201340.","journal-title":"Adv Drug Deliv Rev"},{"key":"4738_CR34","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/S0169-409X(02)00114-X","volume":"54","author":"JA Bouwstra","year":"2002","unstructured":"Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev. 2002;54:S41\u201355.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4738_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.0022-202X.2005.23668.x","volume":"125","author":"PM Elias","year":"2005","unstructured":"Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatology. 2005;125(2):183\u2013200.","journal-title":"J Invest Dermatology"},{"issue":"11","key":"4738_CR36","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261\u20138.","journal-title":"Nat Biotechnol"},{"key":"4738_CR37","doi-asserted-by":"crossref","unstructured":"Ghasemiyeh P. and Soliman Mohammadi-Samani. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: advantages and disadvantages. Drug Des Devel Ther (2020): 3271\u201389.","DOI":"10.2147\/DDDT.S264648"},{"issue":"3","key":"4738_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/10717540500455975","volume":"13","author":"MB Brown","year":"2006","unstructured":"Brown MB, et al. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175\u201387.","journal-title":"Drug Delivery"},{"issue":"11","key":"4738_CR39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrd4333","volume":"13","author":"VP Torchilin","year":"2014","unstructured":"Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discovery. 2014;13(11):813\u201327.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"4738_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","volume":"65","author":"E Touitou","year":"2000","unstructured":"Touitou E, et al. Ethosomes\u2014novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Controlled Release. 2000;65(3):403\u201318.","journal-title":"J Controlled Release"},{"issue":"1","key":"4738_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2004.02.028","volume":"97","author":"DD Verma","year":"2004","unstructured":"Verma DD, Fahr A. Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J Controlled Release. 2004;97(1):55\u201366.","journal-title":"J Controlled Release"},{"key":"4738_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.colsurfb.2011.12.004","volume":"92","author":"C Song","year":"2012","unstructured":"Song C, Kil, et al. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro\/in vivo evaluation. Colloids Surf B. 2012;92:299\u2013304.","journal-title":"Colloids Surf B"},{"key":"4738_CR43","doi-asserted-by":"crossref","unstructured":"Ascenso A et al. Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes. Int J Nanomed (2015): 5837\u201351.","DOI":"10.2147\/IJN.S86186"},{"issue":"1\u20132","key":"4738_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijpharm.2006.05.027","volume":"322","author":"MMA Elsayed","year":"2006","unstructured":"Elsayed MMA, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322(1\u20132):60\u20136.","journal-title":"Int J Pharm"},{"issue":"1","key":"4738_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ddtec.2005.05.003","volume":"2","author":"PL Honeywell-Nguyen","year":"2005","unstructured":"Honeywell-Nguyen PL, Joke A. Bouwstra. Vesicles as a tool for transdermal and dermal delivery. Drug discovery today: Technol. 2005;2(1):67\u201374.","journal-title":"Drug discovery today: Technol"},{"issue":"6","key":"4738_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s11095-021-03053-5","volume":"38","author":"AC Paiva-Santos","year":"2021","unstructured":"Paiva-Santos AC, et al. Ethosomes as nanocarriers for the development of skin delivery formulations: Paiva-Santos et al. Pharm Res. 2021;38(6):947\u201370.","journal-title":"Pharm Res"},{"key":"4738_CR47","unstructured":"Kumar D et al. Transferosome as nanocarrier for drug penetration enhancement across skin: a comparison with liposome and ethosome. Curr Nanomed. 2024."},{"issue":"2","key":"4738_CR48","first-page":"72","volume":"10","author":"S Sheel","year":"2022","unstructured":"Sheel S, et al. Ethosome as a potential transdermal drug delivery system. J Pharm Biol Sci. 2022;10(2):72\u20138.","journal-title":"J Pharm Biol Sci"},{"issue":"5","key":"4738_CR49","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/antiox10050768","volume":"10","author":"M Sguizzato","year":"2021","unstructured":"Sguizzato M, et al. Ethosomes and transethosomes for mangiferin transdermal delivery. Antioxidants. 2021;10(5):768.","journal-title":"Antioxidants"},{"issue":"5","key":"4738_CR50","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/chemistry6050058","volume":"6","author":"B Zhan","year":"2024","unstructured":"Zhan B, et al. Ethosomes: a promising drug delivery platform for transdermal application. Chemistry. 2024;6(5):993\u20131019.","journal-title":"Chemistry"},{"issue":"4","key":"4738_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/gels7040218","volume":"7","author":"M Pandey","year":"2021","unstructured":"Pandey M, et al. Site-specific vesicular drug delivery system for skin cancer: a novel approach for targeting. Gels. 2021;7(4):218.","journal-title":"Gels"},{"issue":"6","key":"4738_CR52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cosmetics11060191","volume":"11","author":"E Musielak","year":"2024","unstructured":"Musielak E, Krajka-Ku\u017aniak V. Liposomes and ethosomes: comparative potential in enhancing skin permeability for therapeutic and cosmetic applications. Cosmetics. 2024;11(6):191.","journal-title":"Cosmetics"},{"key":"4738_CR53","doi-asserted-by":"publisher","first-page":"114817","DOI":"10.1016\/j.colsurfb.2025.114817","volume":"254","author":"MU Rajput","year":"2025","unstructured":"Rajput MU, et al. Enhanced transdermal drug delivery and breast cancer spheroid penetration using hyaluronic acid-coated ethosomes. Colloids Surf B. 2025;254:114817.","journal-title":"Colloids Surf B"},{"issue":"14","key":"4738_CR54","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.2174\/0113892010311407240902050401","volume":"26","author":"M Kahlon","year":"2025","unstructured":"Kahlon M, Singh, et al. Emerging nanotechnology involved in skin cancer: pathogenesis, biomarkers, Ethosomal formulation and future perspective. Curr Pharm Biotechnol. 2025;26(14):2190\u2013205.","journal-title":"Curr Pharm Biotechnol"},{"key":"4738_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-662-47862-2_4","volume-title":"Percutaneous penetration enhancers chemical methods in penetration enhancement: nanocarriers","author":"D Ainbinder","year":"2016","unstructured":"Ainbinder D, Godin B. Ethosomes: enhanced delivery of drugs to and across the skin. Percutaneous penetration enhancers chemical methods in penetration enhancement: nanocarriers. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016. pp. 61\u201375."},{"issue":"2","key":"4738_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0005-2736(92)90402-8","volume":"1112","author":"SL Krill","year":"1992","unstructured":"Krill SL, Knutson K, William I. Higuchi. Ethanol effects on the stratum corneum lipid phase behavior. Biochim et Biophys Acta (BBA)-Biomembranes. 1992;1112(2):273\u201380.","journal-title":"Biochim et Biophys Acta (BBA)-Biomembranes"},{"issue":"1","key":"4738_CR57","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya R, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Delivery. 2022;29(1):1959\u201370.","journal-title":"Drug Delivery"},{"issue":"4","key":"4738_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00232-016-9910-5","volume":"249","author":"S Frandsen","year":"2016","unstructured":"Frandsen S, Krog, et al. Difference in membrane repair capacity between cancer cell lines and a normal cell line. J Membr Biol. 2016;249(4):569\u201376.","journal-title":"J Membr Biol"},{"key":"4738_CR59","doi-asserted-by":"crossref","unstructured":"Wu J, Xue X, Qu H. Tumor microenvironment-responsive nanoplatforms for enhanced cancer immunotherapy: advances and synergistic strategies. Nano TransMed (2025): 100092.","DOI":"10.1016\/j.ntm.2025.100092"},{"key":"4738_CR60","doi-asserted-by":"publisher","first-page":"149185","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, et al. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185.","journal-title":"J Immunol Res"},{"issue":"30","key":"4738_CR61","doi-asserted-by":"publisher","first-page":"21915","DOI":"10.1039\/D4RA02564D","volume":"14","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, et al. Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights. RSC Adv. 2024;14(30):21915\u201337.","journal-title":"RSC Adv"},{"issue":"1","key":"4738_CR62","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target therapy. 2023;8(1):198.","journal-title":"Signal Transduct Target therapy"},{"issue":"2","key":"4738_CR63","first-page":"100902","volume":"19","author":"Y Huang","year":"2024","unstructured":"Huang Y, Hui Fan, and, Ti H. Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy. Asian J Pharm Sci. 2024;19(2):100902.","journal-title":"Asian J Pharm Sci"},{"key":"4738_CR64","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3390\/cancers16193410","volume":"16","author":"A Ghebremedhin","year":"2024","unstructured":"Ghebremedhin A, et al. Tumor-associated macrophages as major immunosuppressive cells in the tumor microenvironment. Cancers. 2024;16:3410.","journal-title":"Cancers"},{"issue":"12","key":"4738_CR65","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1039\/D1NR06991H","volume":"14","author":"B Ferdows","year":"2022","unstructured":"Ferdows B, Emiliano, et al. RNA cancer nanomedicine: nanotechnology-mediated RNA therapy. Nanoscale. 2022;14(12):4448\u201355.","journal-title":"Nanoscale"},{"issue":"1","key":"4738_CR66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-022-01528-6","volume":"21","author":"PR Pandey","year":"2022","unstructured":"Pandey PR, et al. RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics. Mol Cancer. 2022;21(1):58.","journal-title":"Mol Cancer"},{"issue":"19","key":"4738_CR67","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2217\/nnm-2022-0130","volume":"17","author":"NN Parayath","year":"2022","unstructured":"Parayath NN, Gandham SK, Amiji MM. Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance. Nanomedicine. 2022;17(19):1355\u201373.","journal-title":"Nanomedicine"},{"issue":"8","key":"4738_CR68","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/cells8080803","volume":"8","author":"JC Chamcheu","year":"2019","unstructured":"Chamcheu JC, et al. Role and therapeutic targeting of the PI3K\/Akt\/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8(8):803.","journal-title":"Cells"},{"key":"4738_CR69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.007","volume":"128","author":"AJ Stratigos","year":"2020","unstructured":"Stratigos AJ, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 1. epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60\u201382.","journal-title":"Eur J Cancer"},{"issue":"7203","key":"4738_CR70","first-page":"436","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436\u201344.","journal-title":"Cancer-related Inflamm Nat"},{"issue":"11","key":"4738_CR71","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1021\/acs.molpharmaceut.3c00286","volume":"20","author":"P Sa","year":"2023","unstructured":"Sa P, et al. Phytochemical-based nanomedicine for targeting tumor microenvironment and inhibiting cancer chemoresistance: recent advances and pharmacological insights. Mol Pharm. 2023;20(11):5254\u201377.","journal-title":"Mol Pharm"},{"issue":"4","key":"4738_CR72","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","volume":"61","author":"P Agostinis","year":"2011","unstructured":"Agostinis P, et al. Photodynamic therapy of cancer: an update. Cancer J Clin. 2011;61(4):250\u201381.","journal-title":"Cancer J Clin"},{"issue":"7","key":"4738_CR73","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc1894","volume":"6","author":"AP Castano","year":"2006","unstructured":"Castano AP, Mroz P. Hamblin. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535\u201345.","journal-title":"Nat Rev Cancer"},{"key":"4738_CR74","first-page":"N-A","volume":"5","author":"F dos Santos Anc\u00e9ly","year":"2019","unstructured":"dos Santos Anc\u00e9ly F et al. Photodynamic therapy in cancer treatment-an update review. J Cancer Metastasis Treatm. 2019;5:N-A.","journal-title":"J Cancer Metastasis Treatm"},{"issue":"6","key":"4738_CR75","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Si-ping Han. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discovery. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discovery"},{"key":"4738_CR76","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U. Katalin Karik\u00f3, and \u00d6zlem T\u00fcreci. mRNA-based therapeutics: developing a new class of drugs. Nat Rev Drug Discovery. 2014;13:759\u201380.","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"4738_CR77","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Paul Workman. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679\u201392.","journal-title":"Nat Biotechnol"},{"key":"4738_CR78","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga Jos\u00e9. Hyman. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309.","journal-title":"Nature"},{"issue":"11","key":"4738_CR79","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.3390\/pharmaceutics15112577","volume":"15","author":"S Kim","year":"2023","unstructured":"Kim S, et al. Innovative topical patches for non-melanoma skin cancer: current challenges and key formulation considerations. Pharmaceutics. 2023;15(11):2577.","journal-title":"Pharmaceutics"},{"key":"4738_CR80","doi-asserted-by":"publisher","first-page":"101556","DOI":"10.1016\/j.jddst.2020.101556","volume":"56","author":"F Gamal","year":"2020","unstructured":"Gamal F, Amr, et al. Control of basal cell carcinoma via positively charged ethosomes of Vismodegib: in vitro and in vivo studies. J Drug Deliv Sci Technol. 2020;56:101556.","journal-title":"J Drug Deliv Sci Technol"},{"key":"4738_CR81","doi-asserted-by":"publisher","first-page":"888","DOI":"10.6004\/jnccn.2010.0066","volume":"8","author":"T Mudigonda","year":"2010","unstructured":"Mudigonda T, et al. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw. 2010;8:888\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4738_CR82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40204-017-0064-z","volume":"6","author":"LB Naves","year":"2017","unstructured":"Naves LB, et al. Nanotechnology for the treatment of melanoma skin cancer. Prog Biomater. 2017;6(1):13\u201326.","journal-title":"Prog Biomater"},{"issue":"1","key":"4738_CR83","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/ajd.12205","volume":"56","author":"C Gaulin","year":"2015","unstructured":"Gaulin C, Sebaratnam DF, Pablo F-P. Quality of life in non\u2010melanoma skin cancer. Australas J Dermatol. 2015;56(1):70\u20136.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"4738_CR84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7861\/clinmedicine.16-1-62","volume":"16","author":"LL Griffin","year":"2016","unstructured":"Griffin LL, Ali FR, John T. Lear. Non-melanoma skin cancer. Clin Med. 2016;16(1):62\u20135.","journal-title":"Clin Med"},{"issue":"2","key":"4738_CR85","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15212\/bioi-2021-0016","volume":"2","author":"C Zheng","year":"2021","unstructured":"Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. Bio Integr. 2021;2(2):57.","journal-title":"Bio Integr"},{"key":"4738_CR86","doi-asserted-by":"crossref","unstructured":"Zhao T et al. Nanocosmeceuticals for dermatological and aesthetic applications: bridging material innovation with clinical and regulatory translation. ACS Nano Med. 2025.","DOI":"10.1021\/acsnanomed.5c00046"},{"issue":"11","key":"4738_CR87","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/pharmaceutics16111384","volume":"16","author":"Y Kang","year":"2024","unstructured":"Kang Y, et al. Nanocarrier-based transdermal drug delivery systems for dermatological therapy. Pharmaceutics. 2024;16(11):1384.","journal-title":"Pharmaceutics"},{"key":"4738_CR88","doi-asserted-by":"publisher","first-page":"173691","DOI":"10.1016\/j.ejphar.2020.173691","volume":"890","author":"A Ramanunny","year":"2021","unstructured":"Ramanunny A, Kadukkattil, et al. Nanocarriers for treatment of dermatological diseases: principle, perspective and practices. Eur J Pharmacol. 2021;890:173691.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4738_CR89","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1002\/kjm2.70130","volume":"42","author":"Yu","year":"2026","unstructured":"Yu, Huang-Ping, et al. Nanotechnology in skin cancer therapy: recent progress in targeted delivery. Kaohsiung J Med Sci. 2026;42(1):e70130.","journal-title":"Kaohsiung J Med Sci"},{"key":"4738_CR90","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3892\/etm.2021.9967","volume":"21","author":"S Volovat","year":"2021","unstructured":"Volovat S, Ruxandra, et al. Nanomedicine to modulate immunotherapy in cutaneous melanoma. Experim Therap Med. 2021;21:535.","journal-title":"Experimental Therapeutic Med"},{"key":"4738_CR91","doi-asserted-by":"crossref","unstructured":"Wen F et al. Precision nanomedicine for cancer: innovations, strategies, and translational challenges. OncoTargets Therapy. 2025:1125\u201348.","DOI":"10.2147\/OTT.S550104"},{"key":"4738_CR92","doi-asserted-by":"crossref","unstructured":"Sun H et al. Tumor microenvironment-responsive nanoparticles: promising cancer PTT carriers. Int J Nanomed. 2025:7987\u20138001.","DOI":"10.2147\/IJN.S526497"},{"key":"4738_CR93","doi-asserted-by":"publisher","first-page":"100068","DOI":"10.1016\/j.ntm.2024.100068","volume":"4","author":"LA Jadhav","year":"2025","unstructured":"Jadhav LA, Satish K. Mandlik. Nanocarriers in skin cancer treatment: emerging drug delivery approaches and innovations. Nano TransMed. 2025;4:100068.","journal-title":"Nano TransMed"},{"issue":"1","key":"4738_CR94","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12672-025-02469-4","volume":"16","author":"P Samathoti","year":"2025","unstructured":"Samathoti P, et al. The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations: a narrative review. Discover Oncol. 2025;16(1):697.","journal-title":"Discover Oncol"},{"key":"4738_CR95","doi-asserted-by":"publisher","first-page":"1331895","DOI":"10.3389\/fmed.2024.1331895","volume":"11","author":"ML Wei","year":"2024","unstructured":"Wei ML, et al. Artificial intelligence and skin cancer. Front Med. 2024;11:1331895.","journal-title":"Front Med"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04738-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:02:21Z","timestamp":1792674141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04738-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04738-9","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"549"}}